ArriVent BioPharma (AVBP): Among the Best Short Squeeze Stocks to Buy According to Analysts [Yahoo! Finance]
ArriVent BioPharma, Inc. (AVBP)
Company Research
Source: Yahoo! Finance
BioPharma, Inc. (NASDAQ: AVBP ) compares to the other top short squeeze stocks that have received a Buy rating from analysts. Stock market trading has an ever-changing environment. Short squeeze is among the few phenomena capable of capturing and holding the attention of such markets. The phenomenon involves a heavily shorted stock suddenly experiencing a rapid price increase, urging short sellers to buy shares to cover their positions, thereby accelerating the upward momentum. Astute investors make significant gains out of the scenario upon identifying these opportunities in their early stages. After Donald Trump's ascension to the U.S. Presidency, recent market activities have demonstrated the significance of short squeezes. READ ALSO: 10 Best Short-Term Stocks To Buy Right Now Tariff rates were the first aspect to take a hit and directly impact the stock market after President Trump's arrival in the White House. The U.S. announced a 25% tariff on imports from Mexico and Canad
Show less
Read more
Impact Snapshot
Event Time:
AVBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVBP alerts
High impacting ArriVent BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
AVBP
News
- Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443BPR Newswire
- ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at BTIG Research to a "strong-buy" rating.MarketBeat
- ArriVent BioPharma (NASDAQ:AVBP) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.MarketBeat
- ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
- ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at Truist Financial Corporation to a "strong-buy" rating.MarketBeat
AVBP
Earnings
- 11/10/25 - Miss
AVBP
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/10/25 - Form 10-Q
- 11/10/25 - Form 8-K
- AVBP's page on the SEC website